Population level consumption of cephalosporins and macrolides may select for reduced antimicrobial susceptibility to unrelated antimicrobials in *Neisseria gonorrhoeae*: an ecological analysis

Chris Kenyon

Corresponding author

1. Professor in Sexually Transmitted Infections
HIV/STI Unit,
Institute of Tropical Medicine,
Antwerp,
Belgium
2. Division of Infectious Diseases and HIV Medicine
University of Cape Town
Anzio Road
Observatory 7700
South Africa
ckenyon@itg.be

Abstract

Aims

Previous studies have found positive associations between population level consumption of macrolides/cephalosporins/floroquinolones and *Neisseria gonorrhoeae* sensitivity to the same class of antimicrobial. We hypothesized that these associations may also apply to different classes of antimicrobials.

Methods

Using susceptibility data from 24 countries in the European Gonococcal Antimicrobial Surveillance Programme and antimicrobial consumption data from the IMS Health MIDAS database we built mixed effects linear regression models with country-level cephalosporin, quinolone and macrolide consumption (standard doses/ 1000 population/ year) as the explanatory variables (from 2009 to 2015) and 1-year lagged ceftriaxone, azithromycin and ciprofloxacin geometric mean minimum inhibitory concentrations and percent resistance as the outcome variables (2010 to 2016).

Results

Positive associations were found between the consumption of cephalosporins and geometric mean MIC ceftriaxone, cefixime and ciprofloxacin. Macrolide consumption was associated with cefixime and ciprofloxacin geometric mean MIC as well as the prevalence of antimicrobial resistance to ciprofloxacin and cefixime.

Conclusions

Population level consumption of cephalosporins and macrolides may select for reduced antimicrobial susceptibility to unrelated antimicrobials.

Word Count: 1721

Background

Neisseria gonorrhoeae (Ng) has acquired antimicrobial resistance to most classes of antimicrobials, including combined high level resistance to ceftriaxone and azithromycin [1, 2]. Both in vitro and individual level studies have established a link between antimicrobial exposure and the development of antimicrobial resistance (AMR) in Ng [3-10]. Antimicrobials used to treat Ng (and other STIs) are one important determinant of AMR in Ng [11, 12].

The consumption of antimicrobials in the general population (bystander selection) is another determinant. A study of all countries contributing data to the World Health Organizations Global Gonococcal Antimicrobial Surveillance Programme found positive associations between the consumption and resistance for cephalosporins, macrolides and quinolones [13]. A previous ecological study of 24 countries in Europe found that the population-level consumption of cephalosporins was associated with the Ng geometric mean MIC of ceftriaxone and cefixime [14]. Likewise, fluoroquinolone consumption was positively associated with the prevalence of fluoroquinolone resistance.

Using the same dataset as this previous study, we aimed to test the hypothesis that the consumption of antimicrobials in the general population induces AMR in Ng to unrelated antimicrobials. A number of in vitro and epidemiological studies have revealed this effect for a range of other bacterial species [15-18]. A case control study of risk factors associated with Methicillin Resistant *Staphylococcus Aureus* (MRSA) infection, for example, found that exposure to any antibiotic in the preceding year was associated with an

approximate tripling of the risk of MRSA [19]. This effect was strongest for quinolones and macrolides, rather than β -lactams. The activation of multidrug efflux pumps plays an important role in the induction of non-homologous resistance. β -lactams can, for example, select for resistance to quinolones (and vice versa) in *Pseudomonas aeruginosa* via this mechanism [17]. A detailed in vitro study of the pathways of cross-resistance in *Escherichia coli*, revealed that single antimicrobial exposure led to multidrug resistance in the majority of antimicrobial pairs tested [20]. Of relevance to our study, macrolides, quinolones and cephalosporins were all found to induce AMR to one another. At a population level, studies from Spain, have found that macrolides were more important drivers for local differences in both erythromycin and penicillin resistance in *Streptococcus pneumoniae* than β -lactams were [15, 16]. A multi-country European study confirmed these findings and in addition found associations between quinolone consumption and erythromycin and penicillin resistance in *S. pneumoniae* [21]. Whilst epidemiological studies have not established such nonhomologous effects in *Ng*, various considerations make this a worthwhile hypothesis to test. One study found that inactivating the MtrCDE multidrug efflux pump in *Ng* (which can be selected for by cephalosporins and macrolides [22]) results in large reductions in minimum inhibitory concentrations (MICs) to ciprofloxacin (a quinolone), ceftriaxone (a cephalosporin) and azithromycin (a macrolide) [23]. Furthermore a number of studies have found positive associations between AMR to different antimicrobials in isolates of *Ng* [6, 24, 25].

Methods

Our data came from two sources.

Antimicrobial resistance. Euro-GASP includes a sentinel surveillance programme that tests a representative number of isolates from 28 European Union/European Economic Area member states per year for a range of antimicrobials through a biannual hybrid centralised/decentralised system (Table 1). We used the Euro-GASP MIC data for azithromycin, cefixime, ceftriaxone and ciprofloxacin between 2010 and 2016. The full Euro-GASP methodology, including suggested sampling strategy, laboratory techniques, external quality assurance and internal quality control mechanisms has been published elsewhere [26]. The following minimum inhibitory concentration (MIC) breakpoints are used to define antimicrobial resistance in EuroGASP: Azithromycin: >0.5 mg/L, Cefixime: >0.12 mg/L, Ceftriaxone: >0.12 mg/L, Ciprofloxacin: >0.06 mg/L [27, 28].

Antimicrobial consumption. Data from Intercontinental Marketing Statistics Health MIDAS (IMS Health, Danbury, CT, USA) were used as a measure of national antimicrobial drug consumption. IMS uses national sample surveys that are performed by pharmaceutical sales distribution channels to estimate antimicrobial consumption from the volume of antibiotics sold in retail and hospital pharmacies. The sales estimates from this sample are projected with use of an algorithm developed by IMS Health to approximate total volumes for sales and consumption. Antimicrobial consumption estimates are reported as the number of standard doses (a dose is classified as a pill, capsule, or ampoule) per 1000 population per year. Data on consumption of cephalosporins, quinolones and macrolides was available for 34 European

countries. We used data for the 24 countries that were also represented in the Euro-GASP dataset.

Data analysis

For each antimicrobial we calculated the following variables by country and year: 1) Geometric mean MIC of all samples, 2) the percentage of isolates with antimicrobial resistance.

The association between the sensitivities (AMR and MIC) of different antimicrobials at an individual and country level was assessed using mixed effects logistic regression. The MIC values were log transformed to create more normal distributions for these regression analyses.

For each antimicrobial, mixed effects linear regression was used to assess the association between antimicrobial consumption and (1) geometric mean MIC and (2) the percentage of isolates with antimicrobial resistance. All country level mixed effects analyses were weighted by the number of samples used in the analysis.

The statistical analyses were performed in R V.3.3.2 and Stata 13.0.

Results

The number of countries with antimicrobial consumption data reported increased from 19 countries in 2009 to 24 countries in 2015 (Table 1). Likewise, the completeness of data for AMR improved by year for all

antimicrobials (details reported in [14]). Large variations in antimicrobial consumption and AMR were evident between countries. These have been reported elsewhere [14, 21].

Associations between sensitivities of different antimicrobials

Individual isolate level: AMR for all four antimicrobials assessed were statistically significantly positively associated with one another (coef. from 0.15 (95% confidence interval [CI] 0.07-0.22) to 2.2 (95% CI 1.9-2.6) all $P < 0.05$; Table 2). The same was true for the log transformed MIC values (coef. from 0.05 to 2.3; all $P < 0.005$; Table 2).

Country level: Azithromycin resistance was a significant predictor of resistance to cefixime (coef. 0.18; $P < 0.05$) and ciprofloxacin (coef. 0.31; $P < 0.05$; Table 3), as was cefixime resistance a predictor for resistance to azithromycin (coef. 5.7; $P < 0.005$), ceftriaxone (coef. 0.03; $P < 0.05$) and ciprofloxacin (coef. 0.79; $P < 0.005$). Ceftriaxone resistance predicted resistance to azithromycin (coef. 6.7; $P < 0.005$) and cefixime (coef. 1.5; $P < 0.05$), whereas ciprofloxacin resistance predicted resistance to cefixime (coef. 0.18; $P < 0.005$) and ceftriaxone (coef. 1.5; $P < 0.05$). The geometric mean MICs of the four antimicrobials were all significantly positively associated with one another excluding the cefixime-ciprofloxacin comparison (coef. 0.003 to 58.3; all $P < 0.05$).

Correlation between antimicrobial sensitivity and consumption

Linear regression analyses revealed positive associations between the consumption of cephalosporins and geometric mean MIC ceftriaxone,

cefixime and ciprofloxacin (all P's < 0.05; Table 4). Macrolide consumption was associated with cefixime and ciprofloxacin geometric mean MIC (all P's < 0.05). Rerunning the models with AMR as the independent variable, macrolide consumption was associated with cefixime resistance (Table 4; P = 0.038) and cephalosporin, macrolide and quinolone consumption were all associated with ciprofloxacin resistance (all P < 0.01).

Discussion

Building on a previous study that found associations between population level consumption of cephalosporins and fluoroquinolones and homologous class susceptibility, we found positive associations between non-homologous class associations. These associations were present at the level of both individual isolates and countries. At an individual level both MICs and antimicrobial resistance for azithromycin, cefixime, ceftriaxone and ciprofloxacin were all positively associated with one another. With a few exceptions, the same was true for geometric mean MIC and the prevalence of antimicrobial resistance at a country level.

We also found positive associations between country-level geometric mean MIC/AMR and of non-homologous class antimicrobial consumption. This effect was most noticeable for macrolides. For example, macrolide consumption was a stronger predictor of ciprofloxacin/cefixime geometric MIC than fluoroquinolone/cephalosporin consumption, respectively.

These findings are commensurate with those from other bacteria where similar associations have been found [21, 29-34]. Both macrolides and quinolones have been found to be associated with β -lactam resistance in other organisms but this is the first time that we are aware of that this effect has been demonstrated in Ng [15-17, 35, 36]. The fact that positive associations between consumption and AMR/MIC were also found at an individual isolate level between all pairs of antimicrobials tested makes these findings less likely to be due to the ecological inference fallacy. Further work is required to test in vitro and at individual and population levels if differential effects of macrolides versus β -lactams on resistant versus sensitive subpopulations of Ng may play a role in macrolides induction of resistance as has been observed for other bacteria [37-39].

There are however a number of other explanations for these findings. The consumption of the three classes of antimicrobials were themselves positively associated with one another which means the positive country level associations we found between non-homologous consumption and reduced susceptibility may be explained by confounding. We did not control for this at country level as it is unclear to us if this would be meaningful in this type of ecological analysis. There were also a large number of other factors responsible for the emergence of AMR which we did not control for [11, 12, 40]. Further study limitations include incomplete data and/or small samples for a number of countries.

If this link between antimicrobial consumption and resistance applies to Ng as well as other bacteria, then this would have important public health consequences. Baquero et al., have argued persuasively that the linked emergence of Extended Spectrum Beta Lactamase (ESBL) resistance in multiple bacterial species in hospitals in Spain was best viewed as a syndemic rather than epidemics of single species or clones [41]. Appreciating this as a syndemic enabled them to address the underlying environmental determinant of AMR: excess use of antimicrobial drugs that induce ESBL production in multiple bacteria species rather than traditional approaches targeting individual clones or species [41, 42]. Likewise, efforts to reduce antimicrobials particularly associated with the genesis of antimicrobial resistance such as macrolides, cephalosporins and fluoroquinolones in Scotland has been shown to have resulted in a reduction in the prevalence of methicillin resistance of *Staphylococcus aureus* [43].

Whilst further in-vitro and clinic-epidemiological studies are required to establish the extent to which cross resistance emerges in Ng our study results provide further motivation to reduce the consumption of antimicrobials, such as macrolides, as far as is possible and safe in the general population.

Competing interests

The author declare that he has no competing interests.

Funding

Nil

Acknowledgements

Data from The European Surveillance System – TESSy, provided by countries listed in Table 1 and released by ECDC

Consent for publication

Not applicable

Disclaimer

The views and opinions of the authors expressed herein do not necessarily state or reflect those of ECDC. The accuracy of the authors' statistical analysis and the findings they report are not the responsibility of ECDC. ECDC is not responsible for conclusions or opinions drawn from the data provided. ECDC is not responsible for the correctness of the data and for data management, data merging and data collation after provision of the data. ECDC shall not be held liable for improper or incorrect use of the data.

Table 1. List of countries included in study and method used to assess antimicrobial sensitivity

Country	Country code	Method of testing	
Austria	AT	Decentralised	Etest
Belgium	BE	Decentralised	AD
Croatia	HR	Centralised	Etest
Czech Rep.	CZ	Decentralised	Etest
Denmark	DE	Decentralised	Etest
Estonia	EE	Centralised	Etest
France	FR	Decentralised	Etest
Germany	DE	Centralised	BKP/Etest
Greece	EL	Decentralised	Etest
Hungary	HU	Centralised	BKP/Etest
Iceland	IS	Decentralised	Etest
Ireland	IE	Decentralised	Etest
Italy	IT	Decentralised	Etest
Latvia	LV	Centralised	Etest
Finland	FI	Decentralised	Etest
Netherlands	NL	Decentralised	Etest
Norway	NO	Decentralised	AD
Poland	PL	Centralised	Etest
Portugal	PT	Decentralised	Etest
Slovakia	SK	Centralised	Etest
Slovenia	SI	Decentralised	Etest
Spain	ES	Decentralised	Etest
Sweden	SE	Decentralised	Etest
UK	UK	Decentralised	AD/Etest

Etest minimum inhibitory concentration (MIC) gradient strips to determine the MIC of an antimicrobial, AD agar dilution method, BKP Breakpoint agar dilution method

Table 2. Adjusted individual isolate level associations: A) between antimicrobial resistance in azithromycin, cefixime, ceftriaxone and ciprofloxacin [coefficients (95% Confidence Intervals) reported; assessed via mixed effects logistic regression]; B) between log transformed geometric mean MIC for azithromycin, cefixime, ceftriaxone and ciprofloxacin [coefficients (95% Confidence Intervals) reported; assessed via mixed effects linear regression]^a. In all the calculations, the row variable is the outcome variable.

Individual isolate level				
	Azithromycin	Cefixime	Ceftriaxone	Ciprofloxacin
A) Antimicrobial Resistance				
Azithromycin	-	0.83 (0.71-0.94)**	0.61 (0.10-1.12)*	0.15 (0.07-0.22)**
Cefixime	0.74 (0.63-0.86)**	-	2.0 (1.5-2.5)**	2.1 (1.8-2.5)**
Ceftriaxone	0.60 (0.09-1.10)*	2.1 (1.6-2.7)**	-	^b
Ciprofloxacin	0.17 (0.010-0.24)**	2.24 (1.87-2.62)**	^b	-
B) MIC				
Azithromycin	-	0.37 (0.34-0.39)**	0.32 (0.31-0.34)**	0.05 (0.05-0.06)**
Cefixime	0.22 (0.21-0.23)**	-	0.54 (0.53-0.54)**	0.11 (0.10-0.11)**
Ceftriaxone	0.32 (0.30-0.34)**	0.90 (0.88-0.91)**	-	0.17 (0.17-0.18)**
Ciprofloxacin	0.69 (0.62-0.75)**	2.3 (2.3-2.3)**	2.2 (2.2-2.3)**	-

^a Adjusted for year of isolate, random intercept for country

*P<0.05 **P<0.005

^b All 26 isolates with ceftriaxone resistance had ciprofloxacin resistance and thus the model did not achieve convergence

Table 3. Country level associations: Mixed effects linear regression of A) percent antimicrobial resistance and B) geometric mean MIC of azithromycin, cefixime, ceftriaxone and ciprofloxacin given the value for the percent resistance/ geometric mean MIC of the other antimicrobial (coefficients). In all cases the row variable is the outcome variable ^a

Country level				
	Azithromycin	Cefixime	Ceftriaxone	Ciprofloxacin
A) Antimicrobial Resistance				
Azithromycin	-	5.73 **	6.71 **	0.08
Cefixime	0.182*	-	1.5 *	0.18 **
Ceftriaxone	0.014	0.031*	-	1.5 *
Ciprofloxacin	0.308*	0.786**	0.162	-
B) Geometric mean MIC				
Azithromycin	-	7.2 **	7.3 **	0.03 *
Cefixime	0.016**	-	0.85**	0.004 **
Ceftriaxone	0.005**	0.238**	-	0.003 **
Ciprofloxacin	3.455*	34.77**	58.28***	-

^a Random intercept for country

* P<0.05 **P<0.005

Table 4. Mixed effects linear regression analyses of relationship between antimicrobial consumption (doses/population) and geometric mean MIC/antimicrobial resistance

Dependent variable	Independent variable	Geometric mean MIC		Antimicrobial resistance	
		Coefficient	P-value	Coefficient	P-value
Y/MIC _{CRO}	C _{Cephalosporin}	0.003	0.003	0.2	0.073
	C _{Macrolide}	0.004	0.072	0.1	0.607
	C _{Quinolone}	0.001	0.068	0.2	0.377
Y/MIC _{CFM}	C _{Cephalosporin}	0.004	0.017	1.6	0.062
	C _{Macrolide}	0.005	0.014	2.3	0.038
	C _{Quinolone}	0.007	0.071	1.9	0.137
Y/MIC _{AZM}	C _{Cephalosporin}	0.04	0.115	1.7	0.257
	C _{Macrolide}	0.01	0.497	3.0	0.086
	C _{Quinolone}	-0.02	0.640	-0.7	0.835
Y/MIC _{CIP}	C _{Cephalosporin}	0.46	<0.0001	2.7	0.001
	C _{Macrolide}	0.51	0.0001	13.2	<0.001
	C _{Quinolone}	0.49	0.063	16.8	0.006

* P<0.05; ** P<0.005; *** P<0.0005; CRO – ceftriaxone, CFM – cefixime, AZM – azithromycin, CIP - Ciprofloxacin

References

1. Public Health England. UK case of *Neisseria gonorrhoeae* with high-level resistance to azithromycin and resistance to ceftriaxone acquired abroad. Health Protection Report Advanced Access Report. 2018;12(11).
2. European Centre for Disease Prevention and Control. Extensively drug-resistant (XDR) *Neisseria gonorrhoeae* in the United Kingdom and Australia. ECDC: Stockholm. 2018.
3. Boslego JW, Tramont EC, Takafuji ET, Diniega BM, Mitchell BS, Small JW, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing *Neisseria gonorrhoeae*. *N Engl J Med*. 1987;317(5):272-8. Epub 1987/07/30. doi: 10.1056/NEJM198707303170504. PubMed PMID: 2955222.
4. Clifton S, Bolt H, Mohammed H, Town K, Furegato M, Cole M, et al. Prevalence of and factors associated with MDR *Neisseria gonorrhoeae* in England and Wales between 2004 and 2015: analysis of annual cross-sectional surveillance surveys. *J Antimicrob Chemother*. 2018. Epub 2018/02/03. doi: 10.1093/jac/dkx520. PubMed PMID: 29394396.
5. Ito M, Deguchi T, Mizutani KS, Yasuda M, Yokoi S, Ito S, et al. Emergence and spread of *Neisseria gonorrhoeae* clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. *Antimicrob Agents Chemother*. 2005;49(1):137-43. Epub 2004/12/24. doi: 10.1128/AAC.49.1.137-143.2005. PubMed PMID: 15616287; PubMed Central PMCID: PMC538884.
6. Kirkcaldy RD, Zaidi A, Hook EW, Holmes KK, Soge O, del Rio C, et al. *Neisseria gonorrhoeae* Antimicrobial Resistance Among Men Who Have Sex With Men and Men Who Have Sex Exclusively With Women: The Gonococcal Isolate Surveillance Project, 2005-2010. *Annals of Internal Medicine*. 2013;158(5). PubMed PMID: ISI:000316057700003.
7. Ohnishi M, Watanabe Y, Ono E, Takahashi C, Oya H, Kuroki T, et al. Spread of a chromosomal cefixime-resistant penA gene among different *Neisseria gonorrhoeae* lineages. *Antimicrob Agents Chemother*. 2010;54(3):1060-7. Epub 2009/12/24. doi: 10.1128/AAC.01010-09. PubMed PMID: 20028823; PubMed Central PMCID: PMC2826007.
8. Tanaka M, Nakayama H, Tunoe H, Egashira T, Kanayama A, Saika T, et al. A remarkable reduction in the susceptibility of *Neisseria gonorrhoeae* isolates to cepheims and the selection of antibiotic regimens for the single-dose treatment of gonococcal infection in Japan. *J Infect Chemother*. 2002;8(1):81-6. Epub 2002/04/17. doi: 10.1007/s101560200011. PubMed PMID: 11957125.
9. Carpenter CM, Bahn JM, et al. Adaptability of gonococcus to four bacteriostatic agents, sodium sulfathiazole, rivanol lactate, promin, and penicillin. *Proc Soc Exp Biol Med*. 1945;60:168-71. Epub 1945/10/01. PubMed PMID: 21004069.
10. Unemo M, Shafer WM. Antimicrobial resistance in *Neisseria gonorrhoeae* in the 21st century: past, evolution, and future. *Clin Microbiol Rev*. 2014;27(3):587-613. doi: 10.1128/CMR.00010-14. PubMed PMID: 24982323; PubMed Central PMCID: PMC4135894.

11. Kirkcaldy RD, Bartoces MG, Soge OO, Riedel S, Kubin G, Del Rio C, et al. Antimicrobial Drug Prescription and *Neisseria gonorrhoeae* Susceptibility, United States, 2005-2013. *Emerg Infect Dis.* 2017;23(10):1657-63. Epub 2017/09/21. doi: 10.3201/eid2310.170488. PubMed PMID: 28930001; PubMed Central PMCID: PMC5621530.
12. Unemo M, Del Rio C, Shafer WM. Antimicrobial Resistance Expressed by *Neisseria gonorrhoeae*: A Major Global Public Health Problem in the 21st Century. *Microbiol Spectr.* 2016;4(3). doi: 10.1128/microbiolspec.E110-0009-2015. PubMed PMID: 27337478; PubMed Central PMCID: PMC5492008.
13. Kenyon C, Buyze J, Wi T. Antimicrobial consumption and susceptibility of *Neisseria gonorrhoeae*: a global ecological analysis. (In Submission).
14. Kenyon C, Buyze J, Spiteri G, Cole MJ, Unemo M. Population-Level Antimicrobial Consumption Is Associated With Decreased Antimicrobial Susceptibility in *Neisseria gonorrhoeae* in 24 European Countries: An Ecological Analysis. *J Infect Dis.* 2020;221(7):1107-16. Epub 2019/04/09. doi: 10.1093/infdis/jiz153. PubMed PMID: 30957153.
15. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Dal-Re R. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in *Streptococcus pneumoniae*. *J Clin Microbiol.* 2002;40(1):159-64. Epub 2002/01/05. PubMed PMID: 11773111; PubMed Central PMCID: PMC120130.
16. Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C, Baquero F, Aguilar L, Dal-Re R, et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. *Antimicrob Agents Chemother.* 2005;49(5):1965-72. Epub 2005/04/28. doi: 10.1128/AAC.49.5.1965-1972.2005. PubMed PMID: 15855520; PubMed Central PMCID: PMC1087652.
17. Radberg G, Nilsson LE, Svensson S. Development of quinolone-imipenem cross resistance in *Pseudomonas aeruginosa* during exposure to ciprofloxacin. *Antimicrob Agents Chemother.* 1990;34(11):2142-7. Epub 1990/11/01. PubMed PMID: 2127345; PubMed Central PMCID: PMC172014.
18. Lai CC, Wang CY, Chu CC, Tan CK, Lu CL, Lee YC, et al. Correlation between antibiotic consumption and resistance of Gram-negative bacteria causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009. *J Antimicrob Chemother.* 2011;66(6):1374-82. Epub 2011/03/26. doi: 10.1093/jac/dkr103. PubMed PMID: 21436153.
19. Schneider-Lindner V, Delaney JA, Dial S, Dascal A, Suissa S. Antimicrobial drugs and community-acquired methicillin-resistant *Staphylococcus aureus*, United Kingdom. *Emerg Infect Dis.* 2007;13(7):994-1000. Epub 2008/01/25. doi: 10.3201/eid1307.061561. PubMed PMID: 18214170; PubMed Central PMCID: PMC2878234.
20. Lazar V, Nagy I, Spohn R, Csorgo B, Gyorki A, Nyerges A, et al. Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network. *Nat Commun.* 2014;5:4352. Epub 2014/07/09. doi: 10.1038/ncomms5352. PubMed PMID: 25000950; PubMed Central PMCID: PMC4102323.
21. van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al. Antimicrobial drug use and resistance in Europe. *Emerg Infect Dis.* 2008;14(11):1722-30. Epub 2008/11/04. doi:

- 10.3201/eid1411.070467. PubMed PMID: 18976555; PubMed Central PMCID: PMCPMC2630720.
22. Demczuk W, Martin I, Peterson S, Bharat A, Van Domselaar G, Graham M, et al. Genomic Epidemiology and Molecular Resistance Mechanisms of Azithromycin-Resistant *Neisseria gonorrhoeae* in Canada from 1997 to 2014. *J Clin Microbiol.* 2016;54(5):1304-13. doi: 10.1128/JCM.03195-15. PubMed PMID: 26935729; PubMed Central PMCID: PMCPMC4844716.
23. Golparian D, Shafer WM, Ohnishi M, Unemo M. Importance of multidrug efflux pumps in the antimicrobial resistance property of clinical multidrug-resistant isolates of *Neisseria gonorrhoeae*. *Antimicrob Agents Chemother.* 2014;58(6):3556-9. doi: 10.1128/AAC.00038-14. PubMed PMID: 24733458; PubMed Central PMCID: PMCPMC4068427.
24. Liebowitz LD, Ballard RC, Koornhof HJ. In vitro susceptibility and cross-resistance of South African isolates of *Neisseria gonorrhoeae* to 14 antimicrobial agents. *Antimicrob Agents Chemother.* 1982;22(4):598-603. Epub 1982/10/01. PubMed PMID: 6817704; PubMed Central PMCID: PMCPMC183799.
25. de Vries H, Van der Helm J, van der Loeff MS, Van Dam A. Multidrug-resistant *Neisseria gonorrhoeae* with reduced cefotaxime susceptibility is increasingly common in men who have sex with men, Amsterdam, the Netherlands. *Euro surveillance.* 2009;14(37):3.
26. Spiteri G, Cole M, Unemo M, Hoffmann S, Ison C, van de Laar M. The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)--a sentinel approach in the European Union (EU)/European Economic Area (EEA). *Sex Transm Infect.* 2013;89 Suppl 4:iv16-8. Epub 2013/11/28. doi: 10.1136/sextrans-2013-051117. PubMed PMID: 24243874.
27. Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, et al. Antimicrobial resistance in *Neisseria gonorrhoeae*: Global surveillance and a call for international collaborative action. *PLoS Med.* 2017;14(7):e1002344. Epub 2017/07/08. doi: 10.1371/journal.pmed.1002344. PubMed PMID: 28686231; PubMed Central PMCID: PMCPMC5501266.
28. European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe, 2015. . Stockholm: ECDC; 2017.
29. Hicks LA, Chien YW, Taylor TH, Jr., Haber M, Klugman KP, Active Bacterial Core Surveillance T. Outpatient antibiotic prescribing and nonsusceptible *Streptococcus pneumoniae* in the United States, 1996-2003. *Clin Infect Dis.* 2011;53(7):631-9. Epub 2011/09/06. doi: 10.1093/cid/cir443. PubMed PMID: 21890767.
30. Bronzwaer SL, Cars O, Buchholz U, Molstad S, Goettsch W, Veldhuijzen IK, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. *Emerg Infect Dis.* 2002;8(3):278-82. Epub 2002/04/03. doi: 10.3201/eid0803.010192. PubMed PMID: 11927025; PubMed Central PMCID: PMCPMC2732471.
31. Riedel S, Beekmann SE, Heilmann KP, Richter SS, Garcia-De-Lomas J, Ferech M, et al. Antimicrobial use in Europe and antimicrobial resistance in *Streptococcus pneumoniae*. *European Journal of Clinical Microbiology & Infectious Diseases.* 2007;26(7):485-90. doi: 10.1007/s10096-007-0321-5. PubMed PMID: WOS:000247930300007.

32. Goossens H, Ferech M, Vander Stichele R, Elseviers M, Group EP. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *Lancet*. 2005;365(9459):579-87. Epub 2005/02/15. doi: 10.1016/S0140-6736(05)17907-0. PubMed PMID: 15708101.
33. Bruyndonckx R, Hens N, Aerts M, Goossens H, Cortinas Abrahantes J, Coenen S. Exploring the association between resistance and outpatient antibiotic use expressed as DDDs or packages. *J Antimicrob Chemother*. 2015;70(4):1241-4. Epub 2015/01/15. doi: 10.1093/jac/dku525. PubMed PMID: 25585511.
34. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. *Proc Natl Acad Sci U S A*. 2018;115(15):E3463-E70. Epub 2018/03/28. doi: 10.1073/pnas.1717295115. PubMed PMID: 29581252; PubMed Central PMCID: PMC5899442.
35. Sanders CC, Sanders WE, Jr., Goering RV, Werner V. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. *Antimicrob Agents Chemother*. 1984;26(6):797-801. Epub 1984/12/01. PubMed PMID: 6098219; PubMed Central PMCID: PMC180026.
36. Masuda N, Ohya S. Cross-resistance to meropenem, cephems, and quinolones in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 1992;36(9):1847-51. Epub 1992/09/01. PubMed PMID: 1416876; PubMed Central PMCID: PMC192198.
37. Samore MH, Lipsitch M, Alder SC, Haddadin B, Stoddard G, Williamson J, et al. Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. *American journal of epidemiology*. 2005;163(2):160-70.
38. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. *Lancet Respir Med*. 2013;1(3):262-74. Epub 2014/01/17. doi: 10.1016/S2213-2600(13)70038-9. PubMed PMID: 24429132.
39. Pankuch GA, Jueneman SA, Davies TA, Jacobs MR, Appelbaum PC. In vitro selection of resistance to four beta-lactams and azithromycin in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother*. 1998;42(11):2914-8. Epub 1998/10/31. PubMed PMID: 9797225; PubMed Central PMCID: PMC105965.
40. Kenyon C. Risks of antimicrobial resistance in *N. gonorrhoeae* associated with intensive screening programs in PrEP programmes. *Clinical Infectious Diseases*. 2018. doi: 10.1093/cid/ciy048/4821305.
41. Baquero F, Coque TM, Canton R. Allodemics. *Lancet Infect Dis*. 2002;2(10):591-2. Epub 2002/10/18. PubMed PMID: 12383608.
42. Baquero F, Tedim AP, Coque TM. Antibiotic resistance shaping multi-level population biology of bacteria. *Front Microbiol*. 2013;4:15. Epub 2013/03/20. doi: 10.3389/fmicb.2013.00015. PubMed PMID: 23508522.
43. Lawes T, Lopez-Lozano JM, Nebot C, Macartney G, Subbarao-Sharma R, Dare CR, et al. Turning the tide or riding the waves? Impacts of antibiotic stewardship and infection control on MRSA strain dynamics in a Scottish region over 16 years: non-linear time series analysis. *BMJ Open*. 2015;5(3):e006596. Epub 2015/03/31. doi: 10.1136/bmjopen-2014-006596. PubMed PMID: 25814495; PubMed Central PMCID: PMC4386222.